Home › Therapeutic areas › Oncology › Prostate Cancer
Prostate Cancer (22 companies)
Companies with an active program in Prostate Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 1 | Approved | $202M | 5 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $28.6M | 8 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $880M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | $1.27B | 6 |
| APVO | Aptevo Therapeutics | Oncology | 2 | Phase 1 | $2.2M | 8 |
| ARVN | Arvinas | NeurologyOncology Rare | 2 | Approved | $420M | 10 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $34.5M | 8 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $670M | 4 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $119M | 4 |
| EIKN | Eikon Therapeutics | Oncology | 3 | Phase 2 | $320M | 13 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $9.15B | 16 |
| JANX | Janux Therapeutics | Oncology | 3 | Phase 1 | $1.08B | 4 |
| KAPA | Kairos Pharma | Oncology | 2 | Phase 2 | — | 13 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $903M | 7 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.67B | 13 |
| OLMA | Olema Pharmaceuticals | Oncology | 1 | Phase 3 | $641M | 3 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $914M | 5 |
| TLX | Telix Pharmaceuticals | Oncology | 9 | Approved | $3.27B | 25 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 2 | Phase 3 | $2.09B | 12 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.68B | 28 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $2.10B | 11 |
No companies match.